NuSkin Enterprises, Inc. (NUS)

From the record

NuSkin Enterprises, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

NuSkin Enterprises, Inc.'s 10 filed years say what it did: revenue went from $2.2 billion in fiscal 2016 to $1.5 billion in fiscal 2025, down 4.3% a year; it rose in 4 of 9 years; the deepest fall was 45% from fiscal 2021 to fiscal 2025; net income was positive in 9 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, NuSkin Enterprises, Inc.'s diluted share count shrank about 0.1% a year, and dividends and buybacks returned about 43% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 3 sales (2 under scheduled 10b5-1 plans) and 1 purchase of their own stock on the open market in the year to 2026-09-30, buying about $53 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, NuSkin Enterprises, Inc. earned about 20 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 73 cents per dollar of everything the company owns. Leverage: it owed about 43 cents per dollar of assets, and net share issuance: its share count grew 1.3% over the year (the filed statements).

From the record

NuSkin Enterprises, Inc.'s standing among 10 graded names in its industry family: revenue of $1.5 billion in fiscal 2025 ranks in the top 45% by size; a net margin of 10.8% ranks in the top 5%; revenue growth of -12.6% a year over the last 3 filed years ranks in the bottom 15% (its annual reports).

From the record

NuSkin Enterprises, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Napierski, Ryan S (President and CEO, as filed), filing under that title since 2021-09-01, 5.2 years (top 28% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 5.4 years (top 21%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 28%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

NuSkin Enterprises, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $239 million against debt of $204 million leaves 2.5% of its assets as net cash, top 15% of its family; cash from operations less capital spending is 3.1% of revenue (top 15%); a gross margin of 69.4% (top 15%); research spending of 0.7% of revenue (bottom 25%) (its annual report).

From the record

NuSkin Enterprises, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -12.6% a year over the last three filed years against -4.3% over all 10, slowing (bottom 31% of its family); the newest year grew -14.3% (bottom 6%); research spending grew -22.6% a year (bottom 38%); capital spending grew -16.6% a year (bottom 44%) (its annual reports). NuSkin Enterprises, Inc. reported 3 product lines in fiscal 2025: Wellness at $689 million (46%), Beauty at $568 million (38%), Other Product Lines at $228 million (15%); 0 of 3 grew against the year before (its annual report).

From the record

NuSkin Enterprises, Inc.'s newest year against its own record: revenue of $1.5 billion in fiscal 2025 came in 2.8% below the $1.5 billion its prior three years' pace pointed to (bottom 21% of its family); net income of $160 million against a prior three-year average of $11 million (top 7%); a net margin of 10.8% against -1.1% before (top 7%) (its annual reports).